Key facts
- This page summarizes Nissim Darvish's Form 3 filing for Chemomab Therapeutics Ltd. (CMMB).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 10 Apr 2026, 16:12.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
The options reported in this row were granted to the Reporting Person by the Issuer on October 28, 2016, and are fully vested and exercisable as of the date of this report.
Footnote F2
The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
Footnote F3
The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
Footnote F4
The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
Footnote F5
The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable in 36 equal monthly installments of 2.77%, such that all options reported in this row will be exercisable on June 14, 2026.
Footnote F6
The options reported in this row were granted to the Reporting Person by the Issuer on June 1, 2024, and are fully vested and exercisable as of the date of this report.
SEC remarks
This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.